The impact of short-term reduction in hepatic triglycerides on vascular health in adults with or at risk of metabolic dysfunction-associated steatotic liver disease
Open Access
- 13 August 2026
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (8) , e0345338
Abstract
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) increases cardiovascular risk, but the vascular benefits of reducing hepatic triglycerides remain unclear. Aim: To determine whether short-term diet-induced reductions in hepatic triglycerides improve arterial stiffness and endothelial function. Methods: In a two-week, two-arm pre-post dietary intervention trial, adults with MASLD or elevated risk were assigned to either a low-carbohydrate (<30 g carbohydrate/day, n = 24) or low-calorie diet (~1,200−1,500 kcal/day, n = 23). Hepatic triglyceride content was assessed using proton density fat fraction magnetic resonance imaging. Vascular assessments included arterial stiffness as assessed by pulse wave velocity (PWV), and endothelial function via brachial artery flow-mediated dilation (FMD). The Framingham Risk Score (FRS) was evaluated pre- and post-intervention. Results: At baseline, 31 of 47 participants had MASLD. In the total sample, hepatic triglyceride content decreased by 15% relative to baseline (p < 0.001), with no significant differences between the two diet groups. Brachial-ankle PWV decreased by 41 cm/s (p = 0.001). FRS decreased (p < 0.001) and FMD (p = 0.030) increased by ~1.0% in absolute terms. Reductions in hepatic triglyceride content were positively correlated with changes in heart rate at rest (r = 0.49, p = 0.001), even after the adjustment of age and body weight change (r = 0.35, p = 0.021). Conclusions: Vascular function improvements and cardiovascular risk reductions occurred along with hepatic triglyceride reduction following a two-week dietary intervention. Changes in hepatic triglyceride content were positively correlated with the corresponding changes in heart rate but not with measures of vascular function. (ClinicalTrials.gov, NCT05216796).Keywords
Funding Information
- University of Texas at Austin ($1,200,000)
This publication has 31 references indexed in Scilit:
- EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)Journal of Hepatology, 2024
- Poor Awareness of Liver Disease Among Adults With NAFLD in the United StatesHepatology Communications, 2021
- Nonalcoholic Fatty Liver Disease and Cardiovascular DiseaseClinical Liver Disease, 2021
- The degree of hepatic steatosis associates with impaired cardiac and autonomic functionJournal of Hepatology, 2019
- Noninvasive, Quantitative Assessment of Liver Fat by MRI‐PDFF as an Endpoint in NASH TrialsHepatology, 2018
- Hepatic vagus nerve regulates Kupffer cell activation via α7 nicotinic acetylcholine receptor in nonalcoholic steatohepatitisJournal of Gastroenterology, 2017
- Small dense LDL cholesterol measured by homogeneous assay in Japanese healthy controls, metabolic syndrome and diabetes patients with or without a fatty liverClinica Chimica Acta, 2015
- Reductions in arterial stiffness with weight loss in overweight and obese young adults: Potential mechanismsAtherosclerosis, 2012
- Use of Carotid Ultrasound to Identify Subclinical Vascular Disease and Evaluate Cardiovascular Disease Risk: A Consensus Statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force Endorsed by the Society for Vascular MedicineJournal of the American Society of Echocardiography, 2008
- Fasting serum insulin and the homeostasis model of insulin resistance (HOMA-IR) in the monitoring of lifestyle interventions in obese personsClinical Biochemistry, 2007